IR@PKUHSC  > 北京大学临床肿瘤学院  > 病理科
学科主题临床医学
Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer
Qi, Meng1; Li, Jin Feng1; Xie, Yun Tao1; Lu, Ai Ping2; Lin, Ben Yao1; Ouyang, Tao1
关键词Breast Cancer Primary Chemotherapy Paclitaxel Schedule Efficacy Toxicity
刊名BREAST CANCER RESEARCH AND TREATMENT
2010-08-01
DOI10.1007/s10549-010-1000-2
123期:1页:197-202
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]NEOADJUVANT CHEMOTHERAPY ; SURVIVAL ; THERAPY
英文摘要

The purpose of this study is to compare the efficacy of weekly paclitaxel to every-3-week schedule in terms of pathologic response and toxicity which caused treatment delay in primary chemotherapy of breast cancer. After pretreatment of two cycles of cyclophosphamide/ pirarubicin/ fluorouracil (cyclophosphamide 500 mg/m(2) days 1, 8; pirarubicin 35 mg/m(2) days 1, 8; 5-Fu 200 mg/m(2) day ci day 1-28, every 4 weeks), 219 women with histologically confirmed T(1-3) N(0-2) M(0) invasive breast cancer, whose vertical diameters production of breast tumor reduced not more than 75%, were randomized to receive four cycles of Pq3wC (arm A: paclitaxel 175 mg/m(2) day 1, carboplatin AUC 6 d1, every 3 weeks) or Pq1wC (arm B: paclitaxel 60 mg/m(2) days 1, 8, 15, carboplatin AUC 6 day 1 for every 3 weeks) before surgery, stratified by partial or no response (stable disease and progression of disease) evaluated by ultrasonography. Pathologic response of the primary tumor was assessed by using Miller and Payne grading system. We defined grade 4/5 as excellent response, grade 3/4/5 as response and treatment delay as paclitaxel administration being delayed at least 1 week because of toxicity in this study. 213 patients (2 cases with concurrent bilateral breast cancer) were eligible for analysis, 109 patients with 110 lesions in arm A and 104 patients with 105 lesions in arm B. Patients in arm B had a higher excellent pathologic response rate and a higher pathologic response rate compared with patients in arm A (59.0 vs. 45.5%, P = 0.046 and 86.7 vs. 71.8%, P = 0.007). Pathologic complete response (pCR) rate in breast alone was similar between two arms (P = 0.733), but there was a higher pCR rate in patients with partial response to two cycles of cyclophosphamide/pirarubicin/fluorouracil than those with no response (32.4 vs. 13.9%, P = 0.001). There was no treatment-related death, however more patients in arm B than in arm A experienced treatment delay caused by toxicity (60.6 vs. 11.9%, P < 0.001). Under the condition of same cumulative doses, weekly paclitaxel was more effective than 3 weeks schedule in terms of pathologic response to primary chemotherapy in breast cancer, and caused more treatment delay related to toxicity though well tolerant.

语种英语
WOS记录号WOS:000280063200023
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56642
专题北京大学临床肿瘤学院_病理科
北京大学临床肿瘤学院_乳腺癌预防治疗中心
作者单位1.Peking Univ, Breast Canc Ctr, Beijing Canc Hosp & Inst,Sch Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Dept Pathol, Beijing Canc Hosp & Inst,Sch Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Qi, Meng,Li, Jin Feng,Xie, Yun Tao,et al. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer[J]. BREAST CANCER RESEARCH AND TREATMENT,2010,123(1):197-202.
APA Qi, Meng,Li, Jin Feng,Xie, Yun Tao,Lu, Ai Ping,Lin, Ben Yao,&Ouyang, Tao.(2010).Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.BREAST CANCER RESEARCH AND TREATMENT,123(1),197-202.
MLA Qi, Meng,et al."Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer".BREAST CANCER RESEARCH AND TREATMENT 123.1(2010):197-202.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Qi, Meng]的文章
[Li, Jin Feng]的文章
[Xie, Yun Tao]的文章
百度学术
百度学术中相似的文章
[Qi, Meng]的文章
[Li, Jin Feng]的文章
[Xie, Yun Tao]的文章
必应学术
必应学术中相似的文章
[Qi, Meng]的文章
[Li, Jin Feng]的文章
[Xie, Yun Tao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。